title: Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women.
abstract: This is a first descriptive, retrospective, observational study aiming to evaluate the changes in bone turnover markers in pregnant women and to assess the effect of a long-term treatment with low-molecular-weight heparin (LMWH), specifically, enoxaparin. Study involved 50 pregnant Caucasian women with thrombophilia. The patients either received prophylactic enoxaparin once daily subcutaneously (N = 35) or were observed without treatment (N = 15). Concentrations of total serum alkaline phosphatase (total AP), bone alkaline phosphatase (bone AP), osteoprotegerin (OPG), and the receptor activator of nuclear factor κB ligand (RANKL) were measured at 15, 25, and 35 weeks of gestation. Total serum AP increased with gestational age. In the group treated with enoxaparin, the percentage of bone AP concentration was lower (P < .05) than in the control group. Serum OPG also increased with gestational age, but no significant difference was found between the groups with- and without treatment. Despite the OPG increased, RANKL did not change.
authors.affiliation: Thrombotic Center and Central Hematological Laboratory, General University Hospital in Prague, Czech Republic. msudrova@centrum.cz
authors.forename: Magda
authors.initials: M
authors.lastname: Sudrová
authors.forename: Jan
authors.initials: J
authors.lastname: Kvasnička
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Kudrnová
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Zenáhlíková
authors.forename: Jiří
authors.initials: J
authors.lastname: Mazoch
authors.forename: Radka
authors.initials: R
authors.lastname: Brzežková
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001842:Bone and Bones / Q000378:metabolism*; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005865:Gestational Age; D006801:Humans; D053244:Osteoprotegerin / Q000097:blood; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood* / Q000517:prevention & control*; D011264:Pregnancy Trimesters / Q000097:blood; D053245:RANK Ligand / Q000097:blood; D012189:Retrospective Studies; D019851:Thrombophilia / Q000097:blood* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D053244:Osteoprotegerin; D053245:RANK Ligand; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D000469:Alkaline Phosphatase